Aldeyra (ALDX) announced that the FDA has accepted for review the resubmitted new drug application for topical ocular reproxalap, an investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act target action date of December 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
- Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
- Aldeyra receives special protocol assessment agreement letter from FDA
- Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
- Aldeyra Resubmits Reproxalap NDA to FDA